サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1798926

イソキサゾリンの世界市場

Isoxazoline

出版日
ページ情報
英文 271 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.37円
イソキサゾリンの世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 271 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

イソキサゾリンの世界市場は2030年までに77億米ドルに達する

2024年に50億米ドルと推定されるイソキサゾリンの世界市場は、分析期間2024-2030年にCAGR 7.7%で成長し、2030年には77億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるフルラナーは、CAGR5.3%を記録し、分析期間終了時には26億米ドルに達すると予想されます。アフォキソラナーセグメントの成長率は、分析期間中CAGR 9.3%と推定されます。

米国市場は14億米ドルと推定、中国はCAGR11.6%で成長予測

米国のイソキサゾリン市場は、2024年には14億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.0％と7.3％と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界のイソキサゾリン市場- 主要動向と促進要因のまとめ

イソキサゾリンが動物用医薬品および寄生虫駆除剤の開発で台頭している理由とは？

イソキサゾリンは、犬や猫のノミやマダニなどの外部寄生虫の治療や予防のために獣医学で広く使用されている化合物の一群を指します。イソキサゾリンベースの分子は、昆虫のGABA-およびグルタミン酸-ゲート塩化物チャネルの選択的拮抗薬として機能し、哺乳類に影響を与えることなく寄生虫の中枢神経系を破壊します。高い特異性、長い作用時間、全身的な有効性により、これらの化合物は局所および経口寄生虫駆除剤に好んで使用されています。

これらの化合物は、旧来の抗寄生虫剤に影響を及ぼす耐性問題に対処するのに特に効果的です。動物用製薬会社は、イソキサゾリン誘導体のチュアブル錠、スポットオン液、注射剤への配合を続けており、飼い主に利便性を提供し、治療コンプライアンスを向上させています。単回投与で複数の寄生虫種を持続的に駆除できることから、臨床医やペットケアの専門家の間でその魅力が広がっています。

製品開発を促進する技術革新と規制当局の承認とは？

イソキサゾリンの新しい誘導体は、活性スペクトルの拡大、副作用の最小化、さまざまな年齢層や犬種における安全性への対応を目的に合成されています。イソキサゾリン系薬剤と心臓病予防薬、殺線虫薬、その他の昆虫成長調節薬との併用療法は、寄生虫を幅広くカバーするために開発中です。このような合剤は予防レジメンを簡素化し、市場導入率を向上させることを目的としています。

様々な世界市場における規制当局の承認により、イソキサゾリンに基づく製品の商業的プレゼンスが強化されています。品質と安全性の厳格な評価により、これらの化合物はその良好なリスク・ベネフィット・プロファイルが認められています。市販後調査や現場でのデータは、長期にわたる獣医学的使用における有効性と安全性を支持し続けています。さらに、コンパニオンアニマルケアへの投資の増加は、製薬会社による新しいブランドおよびジェネリック製剤の導入を促しています。

市場の需要はどこで伸びているのか、そして主なエンドユーザーは誰なのか？

コンパニオンアニマル・ヘルスの需要は、特にノミに感染しやすいペットを室内で飼っている家庭や、マダニが蔓延している地域で拡大しています。ペットの飼い主は、年間投与回数が少なくて済む、信頼性が高く長時間作用する予防薬を求めています。獣医師や動物病院が主な処方者であり、小売薬局や動物病院を通じた流通も拡大しています。

北米と欧州は成熟市場であり、ペットの飼育率の高さ、日常的な予防ケアの実践、規制の明確さに支えられています。アジア太平洋とラテンアメリカは、認知度の向上と獣医学的インフラの整備に伴い、導入が増加しています。新興のペットケア業界では、処方グレードの寄生虫駆除薬へのアクセスが徐々に拡大し、需要をさらに押し上げています。

イソキサゾリン市場の成長の原動力は？

イソキサゾリン市場の成長は、ペット飼育数の増加、長時間作用する効果的な外部寄生虫駆除への需要の増加、動物用医薬品の技術革新の拡大など、いくつかの要因によってもたらされます。薬剤製剤の技術的進歩、安全性プロファイルの改善、複数の寄生虫に対する幅広い有効性が製品の魅力を高めています。

コンパニオンアニマルクリニック、ペットケア小売店、オンライン動物用薬局プラットフォームにおける最終用途の拡大により、アクセシビリティが向上しています。多様な動物種を対象とした組み合わせ製品の開発と規制当局の承認が、使用率をさらに高めています。寄生虫抵抗性とペットのヘルスケアニーズが進化する中、イソキサゾリンベースの寄生虫駆除剤は、現代の獣医予防医療において不可欠な存在であり続ける。

セグメント

化合物（Fluralaner、Afoxolaner、Sarolaner、Lotilaner）;ペットの種類（猫、犬）

調査対象企業の例

  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim
  • Ceva Sante Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • Hitek Animal Health
  • KRKA d.d.
  • Merck Animal Health（MSD AH）
  • Norbrook Laboratories
  • Orion Corporation
  • Ourofino Saude Animal
  • PetIQ, Inc.
  • Phibro Animal Health Corporation
  • Sogeval Laboratories
  • Syngene International Ltd.
  • Vetoquinol S.A.
  • Virbac
  • Zoetis Inc.

AI統合

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38973

Global Isoxazoline Market to Reach US$7.7 Billion by 2030

The global market for Isoxazoline estimated at US$5.0 Billion in the year 2024, is expected to reach US$7.7 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Fluralaner, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Afoxolaner segment is estimated at 9.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 11.6% CAGR

The Isoxazoline market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Isoxazoline Market - Key Trends & Drivers Summarized

Why Is Isoxazoline Gaining Ground in Animal Health and Parasiticide Development?

Isoxazoline refers to a chemical class of compounds widely used in veterinary medicine for the treatment and prevention of ectoparasites such as fleas and ticks in dogs and cats. Isoxazoline-based molecules function as selective antagonists of insect GABA- and glutamate-gated chloride channels, disrupting the central nervous system of parasites without affecting mammals. The high specificity, long duration of action, and systemic efficacy have made these compounds a preferred choice for both topical and oral parasiticide formulations.

These compounds are particularly effective in managing resistance issues that affect older antiparasitic agents. Veterinary pharmaceutical companies continue to formulate isoxazoline derivatives into chewable tablets, spot-on solutions, and injectable formats, offering convenience to pet owners and improving treatment compliance. Their utility in single-dose administration and persistent control across multiple parasite species has expanded their appeal among clinicians and pet care professionals.

What Innovations and Regulatory Approvals Are Advancing Product Development?

New derivatives of isoxazoline are being synthesized to extend spectrum of activity, minimize side effects, and address safety in different age groups and breeds. Combination therapies that pair isoxazolines with heartworm preventatives, nematocides, or other insect growth regulators are under development to provide broader parasitic coverage. These fixed-dose combinations aim to simplify preventive regimens and improve market adoption.

Regulatory approvals in various global markets have strengthened the commercial presence of isoxazoline-based products. With stringent quality and safety evaluations, these compounds have gained recognition for their favorable risk-benefit profile. Post-market surveillance and field data continue to support their efficacy and safety in long-term veterinary use. Further, rising investment in companion animal care is encouraging pharmaceutical companies to introduce new branded and generic isoxazoline formulations.

Where Is Market Demand Growing, and Who Are the Primary End-Users?

Demand is expanding in companion animal health, particularly among households with indoor pets susceptible to flea infestations and regions with endemic tick populations. Pet owners are seeking reliable, long-acting protection that requires fewer administrations per year. Veterinarians and animal hospitals are the primary prescribers, with growing distribution through retail pharmacies and veterinary clinics.

North America and Europe are mature markets, supported by high rates of pet ownership, routine preventive care practices, and regulatory clarity. Asia Pacific and Latin America are witnessing increasing adoption as awareness grows and veterinary infrastructure develops. Emerging pet care industries are gradually expanding access to prescription-grade parasiticides, further boosting demand.

What Is Driving Growth in the Isoxazoline Market?

Growth in the isoxazoline market is driven by several factors including rising pet ownership, increasing demand for long-acting and effective ectoparasite control, and expanding veterinary pharmaceutical innovation. Technological advances in drug formulation, improved safety profiles, and broader efficacy against multiple parasites are enhancing product attractiveness.

End-use expansion in companion animal clinics, pet care retail, and online veterinary pharmacy platforms is improving accessibility. Combination product development and regulatory approvals for diverse animal species are further strengthening usage. As parasite resistance and pet healthcare needs evolve, isoxazoline-based parasiticides are positioned to remain essential in modern veterinary preventive medicine.

SCOPE OF STUDY:

The report analyzes the Isoxazoline market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Chemical Compound (Fluralaner, Afoxolaner, Sarolaner, Lotilaner); Pet Type (Cat, Dog)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim
  • Ceva Sante Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • Hitek Animal Health
  • KRKA d.d.
  • Merck Animal Health (MSD AH)
  • Norbrook Laboratories
  • Orion Corporation
  • Ourofino Saude Animal
  • PetIQ, Inc.
  • Phibro Animal Health Corporation
  • Sogeval Laboratories
  • Syngene International Ltd.
  • Vetoquinol S.A.
  • Virbac
  • Zoetis Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Isoxazoline - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Pet Ownership and Veterinary Care Spending Drive Demand for Isoxazoline-Based Ectoparasiticides
    • Expansion of Companion Animal Flea and Tick Treatment Segments Strengthens Role of Isoxazoline in Oral and Topical Formulations
    • OEM Innovation in Broad-Spectrum Molecules Enhances Efficacy Against Resistant Flea and Mite Populations
    • Growth in Preference for Long-Acting, Monthly Dosing Schedules Throws Spotlight on Systemic Isoxazoline Compounds
    • Increasing Regulatory Approvals for Next-Generation Isoxazolines Supports Rapid Geographic Market Entry
    • OEM Development of Palatable, Species-Specific Delivery Formats Enhances Compliance in Dogs and Cats
    • Rising Incidence of Vector-Borne Diseases in Animals Promotes Preventive Use of Isoxazoline Products
    • OEM Focus on Combination Therapies With Endoparasitic Coverage Expands Utility of Isoxazoline Molecules
    • Surge in E-Commerce Veterinary Drug Sales Supports Access to Isoxazoline-Based Products Without In-Clinic Visits
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Isoxazoline Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Isoxazoline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Fluralaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Fluralaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Fluralaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Afoxolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Afoxolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Afoxolaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Sarolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Sarolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Sarolaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lotilaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lotilaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Lotilaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Dog by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Dog by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Dog by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • JAPAN
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • CHINA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • EUROPE
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Isoxazoline by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • FRANCE
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • GERMANY
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Isoxazoline by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • INDIA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Isoxazoline by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Isoxazoline by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • AFRICA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030

IV. COMPETITION